INCB024360 (Epacadostat) monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: primary results from first-in-Japanese phase I study (KEYNOTE-434)

被引：4
|
作者：
Fujiwara, Yutaka [1 ]
Shitara, Kohei [2 ]
Shimizu, Toshio [1 ]
Yonemori, Kan [1 ]
Matsubara, Nobuaki [2 ]
Ohno, Izumi [2 ]
Kogawa, Takahiro [2 ]
Naito, Yoichi [2 ]
Leopold, Lance [3 ]
Sasahara, Kahori [4 ]
Yatsuzuka, Naoyoshi [4 ]
Takami, Tomoko [4 ]
Shimamoto, Takashi [4 ]
Yamamoto, Noboru [1 ]
Doi, Toshihiko [2 ]
机构：
[1] Natl Canc Ctr, Tokyo, Japan
[2] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[3] Incyte Corp, Wilmington, DE USA
[4] MSD KK, Tokyo, Japan
来源：
MOLECULAR CANCER THERAPEUTICS | 2018年 / 17卷 / 01期
关键词：
D O I：
10.1158/1535-7163.TARG-17-A204
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A204
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Phase I study of IDO1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with atezolizumab in Japanese patients with advanced solid tumors
    Yamamoto, N.
    Fujiwara, Y.
    Kondo, S.
    Iwasa, S.
    Yonemori, K.
    Shimomura, A.
    Kitano, S.
    Shimizu, T.
    Koyama, T.
    Ebata, T.
    Sato, N.
    Nakai, K.
    Inatani, M.
    Tamura, K.
    ANNALS OF ONCOLOGY, 2018, 29
  • [22] Sunitinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors: Updated phase I study results
    Heath, E. I.
    Blumenschein, G. R., Jr.
    Cohen, R. B.
    LoRusso, P. M.
    LoConte, N.
    Kim, S. T.
    Chao, R.
    Wilding, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [23] Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results
    Elisabeth I. Heath
    George R. Blumenschein
    Roger B. Cohen
    Patricia M. LoRusso
    Noelle K. LoConte
    Sindy T. Kim
    Ana Ruiz-Garcia
    Richard C. Chao
    George Wilding
    Cancer Chemotherapy and Pharmacology, 2011, 68 : 703 - 712
  • [24] Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results
    Heath, Elisabeth I.
    Blumenschein, George R., Jr.
    Cohen, Roger B.
    LoRusso, Patricia M.
    LoConte, Noelle K.
    Kim, Sindy T.
    Ruiz-Garcia, Ana
    Chao, Richard C.
    Wilding, George
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 68 (03) : 703 - 712
  • [25] Phase 1 Results From a Study of Romidepsin in Combination With Gemcitabine in Patients With Advanced Solid Tumors
    Jones, Suzanne F.
    Infante, Jeffrey R.
    Spigel, David R.
    Peacock, Nancy W.
    Thompson, Dana S.
    Greco, F. Anthony
    McCulloch, William
    Burris, Howard A., III
    CANCER INVESTIGATION, 2012, 30 (06) : 481 - 486
  • [26] A MULTICENTER OPEN-LABEL PHASE I/LB STUDY OF SO-C101 AS MONOTHERAPY AND IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH SELECTED ADVANCED/METASTATIC SOLID TUMORS
    Marabelle, Aurelien
    Champiat, Stephane
    Garralda, Elena
    Hernando, Alberto
    Janku, Filip
    Raina, Anjali
    Sachse, Richard
    Bechard, David
    Krasnopolskaya, Inna
    Ferrara, Stefano
    LoRusso, Patricia
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A483 - A483
  • [27] Safety and efficacy results from a phase I dose-escalation trial of Nintedanib in combination with Pembrolizumab in patients with advanced solid tumors (PEMBIB trial)
    Varga, Andreea
    Baldini, Capucine
    Martin-Romano, Patricia
    Hollebecque, Antoine
    Gazzah, Anas
    Bahleda, Rastislav
    Menis, Jessica
    Champiat, Stephane
    El-Dakdouki, Yolla
    Paoletti, Xavier
    Ribrag, Vincent
    Michot, Jean-Marie
    Rafie, Saloomeh
    Planchard, David
    Besse, Benjamin
    Massard, Christophe
    Soria, Jean-Charles
    Marabelle, Aurelien
    CANCER RESEARCH, 2018, 78 (13)
  • [28] ARTISTRY-2: a phase 1/2 study of subcutaneously administrated ALKS 4230 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors
    Powderly, John
    Carthon, Bradley
    Ernstoff, Marc
    Olszanski, Anthony
    Liu, Stephen
    Curtis, Kelly
    Du, Yangchun
    Sun, Lei
    Putiri, Emily
    Wang, Yan
    Losey, Heather
    Dezube, Bruce
    Vaishampayan, Ulka
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [29] Safety and efficacy results from a phase I dose-escalation trial of Nintedanib in combination with Pembrolizumab in patients with advanced solid tumors (PEMBIB trial).
    Varga, Andreea
    Baldini, Capucine
    Martin-Romano, Patricia
    Besse, Benjamin
    Planchard, David
    Champiat, Stephane
    Angevin, Eroc
    Hollebecque, Antoine
    Bahleda, Rastislav
    Gazzah, Anas
    Armand, Jean-Pierre
    Paoletti, Xavier
    Massard, Christophe
    Soria, Jean-Charles
    Marabelle, Aurelien
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [30] Phase I study of IBI351 (GFH925) monotherapy in patients with advanced solid tumors: Updated results of the phase I study
    Zhou, Qing
    Yang, Nong
    Zhao, Jun
    Zhao, Mingfang
    Yu, Yan
    Yuan, Ying
    Wang, Huijuan
    Li, Xingya
    Dong, Xiaorong
    Sun, Longhua
    Zhang, Tongmei
    Huang, Dingzhi
    Chu, Qian
    Huang, Jingjing
    Zhang, Sujie
    Huang, Mengna
    Shen, Yuping
    Wu, Yi-Long
    CANCER RESEARCH, 2023, 83 (08)
12345